News Releases | CSL

Month Year

Month Year

Dec 7, 2016

EFFECT-HF demonstrates a significantly beneficial effect of Ferinject® on exercise capacity among patients with chronic heart failure and iron deficiency – confirms findings of previous studies

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Nov 28, 2016

FDA Approves Supplemental New Drug Application for Veltassa® Removing Boxed Warning Regarding Drug-Drug Interactions

PDF VERSION OF PRESS RELEASE Back to overview of Press Release
Nov 24, 2016

Vifor Pharma leads initiatives to raise awareness of Iron Deficiency – 2nd Global Iron Deficiency Day on November 26, 2016

PDF VERSION OF PRESS RELEASE Back to overview of Press Release
Oct 25, 2016

Swissmedic approves ALOXI® for use in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Children in Switzerland

PDF VERSION OF PRESS RELEASE Back to overview of Press Release
Oct 6, 2016

Appointments at the Galenica Group: New management at Vifor Pharma and new Galenica Group CFO designated

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Sep 2, 2016

Galenica completes acquisition of Relypsa, strengthening Vifor Pharma’s position in cardio-renal therapies

PDF VERSION OF PRESS RELEASE Back to overview of Press Release
Sep 1, 2016

Galenica announces Expiration of Cash Tender Offer for Shares of Common Stock of Relypsa

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Aug 9, 2016

Galenica reports double-digit profit growth in the first half of 2016

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Aug 4, 2016

Galenica commences Tender Offer for Relypsa

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Jul 21, 2016

Galenica and Relypsa announce agreement for Galenica to acquire Relypsa. Acquisition strengthens Galenica’s Business unit, Vifor Pharma – an important step towards becoming an independent specialty pharma company

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases

Show per page

Filter by Company: